Bladder cancer
UPDATED --- First-line therapy of synchronous and metachronous metastatic UCaFidel (72 years old)
Fidel, a 72-year-old bus driver, is looking forward to participating in the upcoming national classics car exhibition. He is diagnosed with metastatic bladder cancer during a workup for dysuria.
Assessment summary:
- Former smoker (30 pack years)
- Medical history: hypertension
- CT scan of chest, abdomen and pelvis: bone and lung metastases, biopsy compatible with UCa
- ECOG PS: 1
- No peripheral neuropathy, diabetes mellitus or autoimmune condition
- Audiometric hearing loss: grade 1
- GFR: 90 ml/min
- Cardiac ejection fraction: 60%
- PD-L1 expression: positive
- FGFR2/3 alteration status in metastatic biopsy specimen: wild type
The patient started enfortumab vedotin + pembrolizumab.
- 2 weeks after the first administration: he developed grade 1 maculopapular rash at the site of injection, which self-resolved within a week. No other major side effects were reported.
- Follow-up at 6 months indicated partial response. The patient has now completed 12 cycles of therapy and imaging shows complete remission of the lung metastases, and only 1 small bone lesion remaining.